Kura Oncology (NASDAQ:KURA) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Kura Oncology (NASDAQ:KURA) posted its quarterly earnings results on Wednesday. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11, FiscalAI reports. The business had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative return on equity of 169.73% and a negative net margin of 384.30%.

Here are the key takeaways from Kura Oncology’s conference call:

• KOMZIFTI generated $9.1 million in second-quarter net product revenue, with approximately 115 new patient starts and more than 250 prescriptions. Management said the drug captured a majority of new patient starts in the relapsed/refractory NPM1-mutated AML menin inhibitor market despite launching second.
• KOMZIFTI’s new patient starts increased about 35% sequentially and total prescriptions rose about 60%, while approximately 40% of new starts involved physician-initiated combination use. More than 95% of covered lives have access, including roughly 16 million lives with preferred coverage.
• Clinical data supported ziftomenib’s expansion into frontline AML and combination therapy, including a 94% 12-month overall survival rate in the frontline KOMET-007 dataset. The company expects additional FLT3 combination, long-term venetoclax, and other AML data in the second half of 2026, while pivotal KOMET-017 results remain targeted for 2028.
• Kura ended the quarter with $519 million in cash and short-term investments, down from $667.2 million at year-end 2025, and reported a $68.3 million net loss. Management said available funds plus expected Kyowa Kirin payments should fund the ziftomenib program through 2028, but further development of darlifarnib and potential registrational studies could require disciplined capital allocation or additional financing.
• Darlifarnib produced encouraging early combination data, including a 44% response rate in cabozantinib-exposed renal cell carcinoma and tumor shrinkage in 77% of response-evaluable patients receiving adagrasib in KRAS G12C-mutated cancers. A randomized renal cell carcinoma study is expected to complete enrollment in the first half of 2027, with initial data anticipated in the second half.

Kura Oncology Stock Up 1.5%

Shares of Kura Oncology stock opened at $10.09 on Friday. The firm has a market cap of $895.69 million, a price-to-earnings ratio of -2.99 and a beta of 0.38. Kura Oncology has a one year low of $6.35 and a one year high of $12.49. The stock’s 50-day moving average is $10.17 and its 200 day moving average is $9.32. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Analysts Set New Price Targets

KURA has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Sanford C. Bernstein set a $24.00 target price on shares of Kura Oncology in a research report on Monday, June 15th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. CLSA set a $24.00 price target on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.62.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the sale, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Insigneo Advisory Services LLC acquired a new position in shares of Kura Oncology during the fourth quarter worth approximately $105,000. LPL Financial LLC purchased a new position in Kura Oncology during the fourth quarter worth about $105,000. Jain Global LLC bought a new position in shares of Kura Oncology in the third quarter valued at approximately $91,000. Lazard Asset Management LLC grew its stake in Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company’s stock valued at $92,000 after purchasing an additional 7,189 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after buying an additional 9,958 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.